Imagine Institute For Genetic Disease Hopital Necker
- Address
- 156 Rue De Vaugirard, 75015 Paris, France
Imagine Institute For Genetic Disease Hopital Necker - Advanced Gene Therapy Research
The Imagine Institute at Hopital Necker represents a leading center of excellence in genetic disease research and innovative therapeutic development. The institute specializes in pioneering ex vivo gene therapy approaches for rare genetic disorders, with particular expertise in developing novel treatment strategies for devastating inherited conditions. Their cutting-edge research combines advanced molecular genetics with regenerative medicine techniques to address previously untreatable genetic diseases.
- Ex vivo gene therapy using retroviral vector-mediated genetic correction
- Recessive dystrophic epidermolysis bullosa (RDEB) treatment development
- Autologous skin equivalent grafting and regenerative dermatology
The institute's work focuses on translating laboratory discoveries into clinical applications, particularly in the field of rare genetic skin disorders. Their comprehensive approach includes rigorous long-term safety monitoring protocols extending up to 5 years post-treatment, ensuring both immediate therapeutic efficacy and sustained patient safety. Through their innovative use of COL7A1 gene correction and skin bioengineering, the Imagine Institute is establishing new paradigms in personalized genetic medicine for patients with severe inherited conditions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Imagine Institute For Genetic Disease Hopital Necker
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Phase I/II Clinical Trial of Ex Vivo Gene Therapy Using COL7A1-Encoding SIN Retroviral Vector in Recessive Dystrophic Epidermolysis Bullosa | Institut National De La Sante Et De La Recherche Medicale | Phase I/II | Recruiting | Jan 2025 | — |
IMP list
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| AUTOLOGOUS KERATINOCYTES AND FIBROBLASTS TRANSDUCED WITH A RETROVIRAL VECTOR ENCODING COL7A1 CDNA | 1 | Unknown | 2025-01-29 | 2025-01-29 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.